Abstract | BACKGROUND: METHODS: Patients with unresectable BTC who had pathologically confirmed adenocarcinoma, no prior chemotherapy, Eastern Cooperative Oncology Group (ECOG) performance status ≤1 and measurable disease were enrolled. Treatment consisted of FDR gemcitabine at 800 mg/m(2) on days 1 and 8 every 21 days with capecitabine administered orally b.i.d. in equal doses (650 mg/m(2) b.i.d.) for 14 days (28 doses). RESULTS: Between May 2005 and February 2009, 30 patients were enrolled. The median age was 67 years (45-76) and there were 14 males. Thirty patients were evaluable for response and toxicity. A total of 221 cycles were administered (median 7, range 2-16). One patient achieved complete response and 7 patients achieved partial response, giving an overall response rate of 26.7% in the intention-to-treat population. Twelve patients (40.0%) had stable disease. The median progression-free survival was 6.33 months. The median overall survival was 10.8 months. Grade 3/4 neutropenia and thrombocytopenia were noted in 13 and 7% of the patients, respectively. Grade 2/3 nonhematologic toxicities were asthenia (54% of patients), diarrhea (17%), stomatitis (23%) and hand-foot syndrome (7%). There was no treatment-related death. The drugs taken were skipped at least once in 45% of the patients and the dose was reduced in 26% of them. CONCLUSIONS:
|
Authors | Daniele Santini, Vladimir Virzi, Enrico Vasile, Bruno Vincenzi, Vincenzo Catalano, Francesco Graziano, Gianluca Masi, Giuseppe Bronte, Antonio Russo, Alfredo Falcone, Giuseppe Tonini |
Journal | Oncology
(Oncology)
Vol. 82
Issue 2
Pg. 75-82
( 2012)
ISSN: 1423-0232 [Electronic] Switzerland |
PMID | 22327844
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Copyright | Copyright © 2012 S. Karger AG, Basel. |
Chemical References |
- Deoxycytidine
- Capecitabine
- Fluorouracil
- Gemcitabine
|
Topics |
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Biliary Tract Neoplasms
(drug therapy, mortality, pathology)
- Capecitabine
- Deoxycytidine
(administration & dosage, adverse effects, analogs & derivatives)
- Disease-Free Survival
- Female
- Fluorouracil
(administration & dosage, adverse effects, analogs & derivatives)
- Humans
- Male
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Staging
- Gemcitabine
|